A novel at-home test kit harnesses fluorescence-based detection to identify early-stage bladder cancer with 90 percent accuracy, utilizing urinary hyaluronidases as biomarkers. Developed in South Korea, the device analyzes unprocessed urine samples without pretreatment, overcoming interference from blood proteins. An AI-powered test for bladder cancer, granted FDA breakthrough device designation, employs gas chromatography mass spectrometry to analyze volatile organic compounds in urine. Additionally, a highly sensitive method for detecting circulating tumor DNA in blood suggests promising non-invasive alternatives to biopsies, enhancing cancer diagnostics and patient outcomes.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
